

News Release

Ashland reports financial results¹ for fourth quarter and fiscal year 2021; issues outlook for fiscal year 2022

- Sales of \$591 million, up twelve percent from the prior-year quarter
- Net income of \$43 million, or \$0.72 per diluted share
- Income from continuing operations of \$33 million, or \$0.55 per diluted share
- Adjusted income from continuing operations excluding intangibles amortization expense of \$73 million, or \$1.22 per diluted share
- Adjusted EBITDA of \$149 million
- Cash flows provided by operating activities of \$151 million; free cash flows of \$120 million

WILMINGTON, Del., November 9, 2021 – Ashland Global Holdings Inc. (NYSE: ASH) today announced financial results¹ for the fourth quarter of fiscal year 2021, which ended September 30, 2021, together with its fiscal year 2021 results summary and fiscal year 2022 outlook. The global additives and specialty ingredients company serves customers in a wide range of consumer and industrial markets.

Sales were \$591 million, up twelve percent compared to the prior-year period. Strong demand continued across the company's core, global end markets. Enhanced pricing and the addition of the Schülke & Mayr acquisition also contributed to the growth. These factors were partially offset by the exit of low-margin product lines and reduced sales of hand-sanitizer additives within Personal Care and Household. Global supply-chain and logistics disruptions also limited the company's ability to meet all customer demand. Foreign currency favorably impacted sales by one percent.

Net income was \$43 million compared to \$5 million in the prior-year quarter. Income from continuing operations was \$33 million compared to a loss of \$14 million in the prior-year quarter, or \$0.55 per diluted share compared to a loss of \$0.22 in the prior-year quarter. Adjusted income from continuing operations excluding intangibles amortization expense was \$73 million compared to \$63 million in the prior-year quarter, or \$1.22 per diluted share, up from \$1.03 in the prior-year quarter. Adjusted EBITDA was \$149 million, up from \$131 million in the prior-year quarter.

Cash flows provided by operating activities totaled \$151 million compared to \$132 million in the prior-year quarter. Free cash flows totaled \$120 million which includes a \$16 million inflow associated with the U.S. Accounts Receivable Sales Program and \$9 million of cash restructuring payments. Free cash flows in the prior-year quarter totaled \$89 million which included \$7 million in cash restructuring payments.

"As we indicated with our earnings update on November 1, overall demand during the quarter was strong and the team executed at a high level in the face of continued global supply-chain challenges," said Guillermo Novo, chairman and chief executive officer, Ashland. "Because of these efforts, we were able to achieve sales and earnings results that were consistent with the outlook we had communicated earlier in the fiscal year."

"I am pleased with the progress our team has made executing our strategy, especially in the context of a difficult operating environment," continued Novo. "We experienced cost inflation for energy, freight and raw materials, while supply-chain logistics challenges remained with only slight

improvements in on-time delivery achieved during the quarter. While demand is improving, the persistence of the global pandemic is still impacting consumer behavior. We are focused on capitalizing on the improving demand environment and satisfying incremental demand from our customers while also pursuing appropriate pricing actions to account for the considerable cost inflation we are experiencing. We expect these dynamics to continue into calendar year 2022," added Novo.

"We made excellent progress during the quarter reshaping our portfolio, strengthening our balance sheet and returning capital to shareholders. The announced signing of a definitive agreement to sell the Performance Adhesives business for \$1.65 billion, the establishment of the annual renewable environmental trust, the new \$450 million bond issuance and the \$450 million accelerated share repurchase program are all key milestones as we continue to execute our strategy. I look forward to sharing more insight into our reshaped portfolio and our plans for the future during our live, virtual investor day on November 12," said Novo.

Reportable Segment Performance

To aid in the understanding of Ashland's ongoing business performance, the results of Ashland's reportable segments are described below on an adjusted basis. In addition, EBITDA and adjusted EBITDA are reconciled to operating income in Table 4. Free cash flow and adjusted operating income are reconciled in Table 6 and adjusted income from continuing operations, adjusted diluted earnings per share and adjusted diluted earnings per share excluding intangible amortization expense are reconciled in Table 7 of this news release. These adjusted results are considered non-GAAP financial measures. For a full description of the non-GAAP financial measures used, see the "Use of Non-GAAP Measures" section that further describes these adjustments below.

Discontinued operations accounting

As a result of the previously announced agreement to sell the Performance Adhesives business and plans to report the results of that business as discontinued operations beginning with the fourth quarter results, Ashland has restated its income statement results for fiscal years 2019 and 2020 with the Performance Adhesives business reflected as discontinued operations. The restated income statement was filed with the SEC via a Form 8-K on November 1, 2021. Ashland currently expects the sale of the business to close in the March quarter of 2022.

Life Sciences

Sales were \$189 million, up five percent from the prior-year quarter. Sales growth was driven by strong demand within pharma and nutrition end markets, in addition to enhanced pricing. Foreign currency favorably impacted sales by one percent.

Adjusted operating income was \$31 million, compared to \$36 million in the prior-year quarter. Adjusted EBITDA was \$48 million, down six percent from the prior-year quarter, primarily reflecting unfavorable product mix and raw-material inflation, particularly from higher BDO transfer pricing.

Personal Care and Household

Sales were \$183 million, up twelve percent from the prior-year quarter. Demand and sales growth remained healthy across core personal care end markets. Results for Avoca also improved. The Schülke & Mayr acquisition contributed positively to sales growth in the quarter. This core growth was partially offset by the continued exit from low-margin product lines and reduced sales of hand sanitizer ingredients compared to the prior-year period. Foreign currency had a negligible impact on sales.

Adjusted operating income was \$29 million, compared to \$26 million in the prior-year quarter. Adjusted EBITDA was \$51 million, up eleven percent from the prior-year quarter, as sales growth was partially offset by raw-material inflation, particularly from higher BDO transfer pricing.

Specialty Additives

Sales were \$181 million, up 13 percent from the prior-year quarter, reflecting strong demand for architectural coatings additives and growth within Performance Specialties. Pricing was also favorable across the segment. Foreign currency favorably impacted sales by one percent.

Adjusted operating income was \$25 million, compared to \$23 million in the prior-year quarter. Adjusted EBITDA was \$47 million, up seven percent from the prior-year quarter, as strong sales growth was partially offset by general operating cost inflation.

Intermediates & Solvents

Sales were \$60 million, up 114 percent from the prior-year quarter, driven by higher pricing and volumes for both merchant and captive sales. Captive sales were much higher than the prior-year period reflecting improved demand and the inventory-control measures that occurred last year.

Adjusted operating income was \$18 million, up from \$3 million in the prior-year quarter. Adjusted EBITDA was \$21 million, up from \$6 million in the prior-year quarter, reflecting the higher pricing and volumes and partially offset by higher raw-material cost.

Unallocated & Other

Unallocated and Other expense was \$27 million, compared to \$47 million in the prior-year quarter which included \$22 million of restructuring costs. Adjusted Unallocated and Other expense was \$18 million, compared to \$16 million in the prior-year quarter.

Fiscal Year 2021 Results Summary

Sales were \$2.1 billion, up five percent compared to the prior fiscal year. Demand trends improved throughout the year following the onset of the global pandemic in fiscal year 2020. Sales growth was driven primarily by improved demand, enhanced pricing and the contribution of the Schülke & Mayr acquisition. Foreign currency favorably impacted sales by two percent.

Net income was \$220 million compared to a loss of \$508 million in the prior year which included a goodwill impairment charge of \$530 million. Income from continuing operations was \$173 million compared to a loss of \$555 million in the prior year, or \$2.82 per diluted share compared to a loss of \$9.16 in the prior year. Adjusted income from continuing operations excluding intangibles amortization expense was \$230 million compared to \$179 million in the prior year, or \$3.75 per diluted share, up from \$2.93 in the prior year. Adjusted EBITDA was \$495 million, up from \$449 million in the prior year.

Cash flows provided by operating activities totaled \$466 million compared to \$227 million in the prior year. Free cash flows totaled \$361 million which includes a \$92 million inflow associated with the U.S. Accounts Receivable Program and \$44 million of cash restructuring payments. Free cash flows in the prior year totaled \$94 million which included \$30 million in cash restructuring payments.

Financial Outlook

For fiscal year 2022, the company expects sales in the range of \$2.25 billion to \$2.35 billion and adjusted EBITDA in the range of \$550 million to \$570 million.

"We anticipate improving demand across our businesses and no changes to our underlying operating performance for fiscal year 2022," continued Novo. "While we are seeing meaningful cost inflation for raw materials, freight and energy in addition to persistent supply-chain challenges, our teams are working diligently to implement appropriate pricing actions to offset these dynamics. This is an important year for us to continue executing our strategy and demonstrate consistent organic growth, improving margins and enhanced free cash flow generation. I look forward to sharing more insight into

our outlook for fiscal year 2022 on the conference call webcast with securities analysts tomorrow morning," concluded Novo.

Conference Call Webcast

Ashland will host a live webcast of its fourth-quarter conference call with securities analysts at 9:00 a.m. ET on Wednesday, November 10, 2021. The webcast will be accessible through Ashland's website at http://investor.ashland.com and will include a slide presentation. Following the live event, an archived version of the webcast and supporting materials will be available for 12 months on http://investor.ashland.com.

Investor Day reminder

Ashland will hold a live, virtual investor day on Friday, November 12, 2021 beginning at 9 a.m. ET.

The presentations will outline expectations for Ashland's future performance followed by a live question and answer session and a virtual innovation tradeshow. The virtual tradeshow will allow participants to experience an array of new technologies, innovations and applications that Ashland solvers around the world are contributing to meet customers' needs. During the live event, additional Ashland leaders will be available to participate in virtual question and answer chat sessions. By the start of the live event, Ashland will post the presentation and supporting materials and make them available for 12 months on http://investor.ashland.com.

To participate in Ashland's virtual investor day, please <u>register here</u>.

Use of Non-GAAP Measures

Ashland believes that by removing the impact of depreciation and amortization and excluding certain non-cash charges, amounts spent on interest and taxes and certain other charges that are highly variable from year to year, EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin provide Ashland's investors with performance measures that reflect the impact to operations from trends in changes in sales, margin and operating expenses, providing a perspective not immediately apparent from net income, operating income, net income margin and operating income margin. The adjustments Ashland makes to derive the non-GAAP measures of EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin exclude items which may cause short-term fluctuations in net income and operating income and which Ashland does not consider to be the fundamental attributes or primary drivers of its business. EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin provide disclosure on the same basis as that used by Ashland's management to evaluate financial performance on a consolidated and reportable segment basis and provide consistency in our financial reporting, facilitate internal and external comparisons of Ashland's historical operating performance and its business units and provide continuity to investors for comparability purposes. EBITDA margin and adjusted EBITDA margin are defined as EBITDA and adjusted EBITDA divided by sales for the corresponding period.

Key items, which are set forth on Table 7 of this release, are defined as financial effects from significant transactions that, either by their nature or amount, have caused short-term fluctuations in net income and/or operating income which Ashland does not consider to most accurately reflect Ashland's underlying business performance and trends. Further, Ashland believes that providing supplemental information that excludes the financial effects of these items in the financial results will enhance the investor's ability to compare financial performance between reporting periods.

Tax-specific key items, which are set forth on Table 7 of this release, are defined as financial transactions, tax law changes or other matters that fall within the definition of key items as described above. These items relate solely to tax matters and would only be recorded within the income tax caption of the Statement of Consolidated Income. As with all key items, due to their nature, Ashland

does not consider the financial effects of these tax-specific key items on net income to be the most accurate reflection of Ashland's underlying business performance and trends.

The free cash flow metric enables Ashland to provide a better indication of the ongoing cash being generated that is ultimately available for both debt and equity holders as well as other investment opportunities. Unlike cash flow provided by operating activities, free cash flow includes the impact of capital expenditures from continuing operations, providing a more complete picture of cash generation. Free cash flow has certain limitations, including that it does not reflect adjustment for certain non-discretionary cash flows such as mandatory debt repayments. The amount of mandatory versus discretionary expenditures can vary significantly between periods.

Adjusted diluted earnings per share is a performance measure used by Ashland and is defined by Ashland as earnings (loss) from continuing operations, adjusted for identified key items and divided by the number of outstanding diluted shares of common stock. Ashland believes this measure provides investors additional insights into operational performance by providing earnings and diluted earnings per share metrics that exclude the effect of the identified key items and tax specific key items.

Adjusted diluted earnings per share, excluding intangibles amortization expense metric enables Ashland to demonstrate the impact of non-cash intangibles amortization expense on earnings per share, in addition to key items previously mentioned. Ashland's management believes this presentation is helpful to illustrate how previous acquisitions impact applicable period results.

About Ashland

Ashland Global Holdings Inc. (NYSE: ASH) is a premier additives and specialty ingredients company with a conscious and proactive mindset for sustainability. The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, automotive, construction, energy, food and beverage, nutraceuticals, personal care and pharmaceutical. Approximately 4,100 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit <u>ashland.com</u> and <u>Ashland | Sustainability Overview</u> to learn more.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as "anticipates," "believes," "expects," "estimates," "is likely," "predicts," "projects," "forecasts," "objectives," "may," "will," "should," "plans" and "intends" and the negative of these words or other comparable terminology. Ashland may from time to time make forward-looking statements in its annual reports, quarterly reports and other filings with the U.S. Securities and Exchange Commission (SEC), news releases and other written and oral communications. These forward-looking statements are based on Ashland's expectations and assumptions, as of the date such statements are made, regarding Ashland's future operating performance, financial condition, and expected effects of the COVID-19 pandemic on Ashland's business, as well as the economy and other future events or circumstances. These statements include but may not be limited to Ashland's expectations regarding its ability to drive sales and earnings growth and realize further cost reductions.

Ashland's expectations and assumptions include, without limitation, internal forecasts and analyses of current and future market conditions and trends, management plans and strategies, operating efficiencies and economic conditions (such as prices, supply and demand, cost of raw materials, and the ability to recover raw-material cost increases through price increases), and risks and uncertainties associated with the following: the impact of acquisitions and/or divestitures Ashland has made or may make (including the possibility that Ashland may not realize the anticipated benefits from such transactions); Ashland's substantial indebtedness (including the possibility that such indebtedness and related restrictive covenants may adversely affect Ashland's future cash flows, results of operations, financial condition and its ability to repay debt); severe weather, natural disasters, public-health crises (including the current COVID-19 pandemic), cyber events and legal proceedings and claims (including product recalls, environmental and asbestos matters); the effects of the COVID-19 pandemic on the geographies in which we operate, the end markets we serve and on our supply chain and customers, and

without limitation, risks and uncertainties affecting Ashland that are described in Ashland's most recent Form 10-K (including Item 1A Risk Factors) filed with the SEC, which is available on Ashland's website at http://investor.ashland.com or on the SEC's website at http://www.sec.gov. Various risks and uncertainties may cause actual results to differ materially from those stated, projected or implied by any forward-looking statements. The extent and duration of the COVID-19 pandemic on our business and operations is uncertain. Factors that will influence the impact on our business and operations include the duration and extent of the pandemic, the extent of imposed or recommended containment and mitigation measures, and the general economic consequences of the pandemic. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update any forward-looking statements made in this news release whether as a result of new information, future events or otherwise.

Financial results are preliminary until Ashland's Form 10-K is filed with the U.S. Securities and Exchange Commission.

™ Trademark, Ashland or its subsidiaries, registered in various countries.

FOR FURTHER INFORMATION:

Investor Relations: Seth A. Mrozek +1 (302) 594-5010 samrozek@ashland.com Media Relations: Carolmarie C. Brown +1 (302) 995-3158 ccbrown@ashland.com

Three months ended Year ended September 30 September 30 2021 2020 2021 2020 \$ 591 \$ 529 \$ 2,111 Sales \$ 2,016 401 396 1.441 1.417 Cost of sales **GROSS PROFIT** 190 133 670 599 Selling, general and administrative expense 104 358 400 85 Research and development expense 13 14 50 56 Intangibles amortization expense 21 90 24 84 Equity and other income 2 9 8 Goodwill impairment 530 **OPERATING INCOME (LOSS)** 70 (6)181 (463)Net interest and other expense 38 56 119 6 Other net periodic benefit income (expense) (1)1 (1) 3 Net income on acquisitions and divestitures 11 2 **INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES** 31 (11)135 (577)Income tax expense (benefit) (2)3 (38)(22)**INCOME (LOSS) FROM CONTINUING OPERATIONS** (14)33 173 (555)Income from discontinued operations (net of income taxes) 10 19 47 47 5 **NET INCOME (LOSS)** 43 220 (508)**DILUTED EARNINGS PER SHARE** \$ Income (loss) from continuing operations 0.55 \$ (0.22)\$ 2.82 (9.16)Income from discontinued operations 0.17 0.29 0.77 0.77 Net income (loss) 0.72 0.07 3.59 (8.39)AVERAGE DILUTED COMMON SHARES OUTSTANDING (a) 61 61 61 61 **SALES** Life Sciences 189 180 737 708 Personal Care and Household 183 164 592 615 Specialty Additives 181 160 655 589 Intermediates & Solvents 60 28 178 129 Intersegment Sales (22)(3)(51)(25)529 2,1<u>11</u> \$ 2,016 591 **OPERATING INCOME (LOSS)** 30 26 130 123 Life Sciences Personal Care and Household 73 24 13 (296)Specialty Additives 25 5 61 (132)Intermediates & Solvents 18 35 (10)(3)Unallocated and other (27)(47)(118)(148)70 (6)181 (463)

⁽a) As a result of the loss from continuing operations for the three and twelve months ended September 30, 2020, the effect of the share-based awards convertible to common shares would be anti-dilutive. In accordance with GAAP, these shares have been excluded from the diluted earnings per share calculation for the applicable periods.

Ashland Global Holdings Inc. and Consolidated Subsidiaries CONDENSED CONSOLIDATED BALANCE SHEETS

(In millions - preliminary and unaudited)

(In millions - preliminary and unaudited)	September 30	•					
ASSETS	2021	2020					
Current assets							
Cash and cash equivalents	\$ 210	\$ 454					
Accounts receivable	369						
Inventories	473						
Other assets	68						
Held for sale	597						
Total current assets	1,717						
Noncurrent assets							
Property, plant and equipment							
Cost	3,066	3,002					
Accumulated depreciation	1,639	1,517					
Net property, plant and equipment	1,427						
Goodwill	1,430	1,305					
Intangibles	1,099	1,011					
Operating lease assets, net	124	126					
Restricted investments	384	301					
Asbestos insurance receivable	134						
Deferred income taxes	30						
Noncurrent assets held for sale		546					
Other assets	267						
Total noncurrent assets	4,895						
Total assets	\$ 6,612	\$ 6,877					
LIABILITIES AND EQUITY							
Current liabilities	\$ 365	\$ 280					
Current liabilities Short-term debt	\$ 365 9						
Current liabilities Short-term debt Current portion of long-term debt	9	-					
Current liabilities Short-term debt Current portion of long-term debt Trade and other payables	9 236	211					
Current liabilities Short-term debt Current portion of long-term debt Trade and other payables Accrued expenses and other liabilities	9 236 251	211 272					
Current liabilities Short-term debt Current portion of long-term debt Trade and other payables Accrued expenses and other liabilities Current operating lease obligations	9 236 251 23	211 272 22					
Current liabilities Short-term debt Current portion of long-term debt Trade and other payables Accrued expenses and other liabilities	9 236 251	211 272 22 28					
Current liabilities Short-term debt Current portion of long-term debt Trade and other payables Accrued expenses and other liabilities Current operating lease obligations Held for sale Total current liabilities	9 236 251 23 50	211 272 22 28					
Current liabilities Short-term debt Current portion of long-term debt Trade and other payables Accrued expenses and other liabilities Current operating lease obligations Held for sale Total current liabilities Noncurrent liabilities	9 236 251 23 50 934	211 272 22 28 813					
Current liabilities Short-term debt Current portion of long-term debt Trade and other payables Accrued expenses and other liabilities Current operating lease obligations Held for sale Total current liabilities Noncurrent liabilities Long-term debt	9 236 251 23 50 934	211 272 22 28 813					
Current liabilities Short-term debt Current portion of long-term debt Trade and other payables Accrued expenses and other liabilities Current operating lease obligations Held for sale Total current liabilities Noncurrent liabilities Long-term debt Asbestos litigation reserve	9 236 251 23 50 934 1,596 490	211 272 22 28 813 1,573 513					
Current liabilities Short-term debt Current portion of long-term debt Trade and other payables Accrued expenses and other liabilities Current operating lease obligations Held for sale Total current liabilities Noncurrent liabilities Long-term debt Asbestos litigation reserve Deferred income taxes	236 251 23 50 934 1,596 490 237	211 272 22 28 813 1,573 513 229					
Current liabilities Short-term debt Current portion of long-term debt Trade and other payables Accrued expenses and other liabilities Current operating lease obligations Held for sale Total current liabilities Noncurrent liabilities Long-term debt Asbestos litigation reserve Deferred income taxes Employee benefit obligations	9 236 251 23 50 934 1,596 490 237	211 272 22 28 813 1,573 513 229 157					
Current liabilities Short-term debt Current portion of long-term debt Trade and other payables Accrued expenses and other liabilities Current operating lease obligations Held for sale Total current liabilities Noncurrent liabilities Long-term debt Asbestos litigation reserve Deferred income taxes Employee benefit obligations Operating lease obligations	236 251 23 50 934 1,596 490 237	211 272 22 28 813 1,573 513 229 157					
Current liabilities Short-term debt Current portion of long-term debt Trade and other payables Accrued expenses and other liabilities Current operating lease obligations Held for sale Total current liabilities Noncurrent liabilities Long-term debt Asbestos litigation reserve Deferred income taxes Employee benefit obligations Operating lease obligations Noncurrent liabilities held for sale	1,596 490 237 1,44 110	1,573 513 229 157 114					
Current liabilities Short-term debt Current portion of long-term debt Trade and other payables Accrued expenses and other liabilities Current operating lease obligations Held for sale Total current liabilities Noncurrent liabilities Long-term debt Asbestos litigation reserve Deferred income taxes Employee benefit obligations Operating lease obligations	9 236 251 23 50 934 1,596 490 237	1,573 513 229 157 114 10					
Current liabilities Short-term debt Current portion of long-term debt Trade and other payables Accrued expenses and other liabilities Current operating lease obligations Held for sale Total current liabilities Noncurrent liabilities Long-term debt Asbestos litigation reserve Deferred income taxes Employee benefit obligations Operating lease obligations Noncurrent liabilities held for sale Other liabilities	1,596 490 237 1,44 110	211 272 22 28 813 1,573 513 229 157 114 10 432 3,028					
Current liabilities Short-term debt Current portion of long-term debt Trade and other payables Accrued expenses and other liabilities Current operating lease obligations Held for sale Total current liabilities Noncurrent liabilities Long-term debt Asbestos litigation reserve Deferred income taxes Employee benefit obligations Operating lease obligations Noncurrent liabilities held for sale Other liabilities Total noncurrent liabilities	236 251 23 50 934 1,596 490 237 144 110 - 349 2,926	211 272 22 28 813 1,573 513 229 157 114 10 432 3,028					

Excludes changes resulting from operations acquired or sold.

Three months ended Year ended September 30 September 30 2021 2020 2021 2020 **CASH FLOWS PROVIDED (USED) BY OPERATING ACTIVITIES** FROM CONTINUING OPERATIONS Net income (loss) \$ 43 \$ 5 \$ 220 \$ (508)Income from discontinued operations (net of taxes) (10)(19)(47)(47)Adjustments to reconcile income from continuing operations to cash flows from operating activities Depreciation and amortization 64 60 235 244 Original issue discount and debt issuance cost amortization 3 15 Deferred income taxes (22)(12)(26)(42)Gain from sales of property and equipment (4)Distributions from equity affiliates 2 1 Stock based compensation expense 3 3 15 14 Excess tax benefit on stock based compensation 2 1 Loss on early retirement of debt 16 16 59 (Income) loss from restricted investments 3 (13)(33)(30)Income on acquisitions and divestitures (3)(15)(3)Impairments 3 13 530 Pension contributions (1) (1) (8)(6) Loss (gain) on pension and other postretirement plan remeasurements (1)1 (1) Change in operating assets and liabilities (a) 48 80 110 Total cash flows provided by operating activities from continuing operations 151 466 132 227 CASH FLOWS PROVIDED (USED) BY INVESTING ACTIVITIES FROM CONTINUING OPERATIONS Additions to property, plant and equipment (31)(43)(105)(133)Proceeds from disposal of property, plant and equipment 5 4 5 Purchase of operations - net of cash acquired (309)(1)9 9 Proceeds from sale or restructuring of operations 14 Proceeds from settlement of Company-owned life insurance contracts 91 91 8 Company-owned life insurance payments (4)(4)(6)(6)Net purchase of funds restricted for specific transactions (90)(91)(3) 9 Reimbursements from restricted investments 8 33 35 Proceeds from sale of securities 149 93 5 21 Purchases of securities (93)(5)(149)(21)Proceeds from the settlement of derivative instruments 1 Payments for the settlement of derivative instruments Total cash flows used by investing activities from continuing operations (27)(24)(367)(85)**CASH FLOWS PROVIDED (USED) BY FINANCING ACTIVITIES** FROM CONTINUING OPERATIONS Proceeds from issuance of long-term debt 450 450 804 Repayment of long-term debt (411)(411)(767)Premium on long-term debt repayment (16)(16)(59)Proceeds from (repayment of) short-term debt (166)269 84 115 Repurchase of common stock (450)(450)Debt issuance costs (6)(6)(11)(16)Cash dividends paid (18)(70)(66)Stock based compensation employee withholding taxes paid in cash (7) (1)(1)(7) Total cash flows provided (used) by financing activities from continuing operations (183)(183)(426)9 **CASH PROVIDED (USED) BY CONTINUING OPERATIONS** (59)(75)(327)151 Cash provided (used) by discontinued operations Operating cash flows 10 16 94 (24)Investing cash flows (2) 96 (14)93 Effect of currency exchange rate changes on cash and cash equivalents 2 (1) 1 3 **INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS** 38 222 (52)(244)**CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD** 416 232 262 454 **CASH AND CASH EQUIVALENTS - END OF PERIOD** 210 454 210 454 **DEPRECIATION AND AMORTIZATION** Life Sciences 17 15 64 60 Personal Care and Household 22 20 81 77 Specialty Additives 22 21 85 81 Intermediates & Solvents 13 3 3 14 Unallocated and other 3 60 64 244 235

Three months ended September 30 Adjusted EBITDA - Ashland Global Holdings Inc. 2021 2020 \$ 43 \$ Net income 5 Income tax expense (benefit) (2)3 Net interest and other expense 38 6 Depreciation and amortization 60 64 **EBITDA** 143 74 Income from discontinued operations (net of taxes) (10)(19)(Income) loss on pension and other postretirement plan remeasurements 1 (1) Operating key items (see Table 5) 15 77 Adjusted EBITDA 149 \$ 131 Adjusted EBITDA - Life Sciences Operating income \$ 30 \$ 26 Add: 17 Depreciation and amortization 15 Operating key items (see Table 5) 10 1 Adjusted EBITDA 48 \$ 51 Adjusted EBITDA - Personal Care and Household \$ Operating income 24 \$ 13 Add: 22 20 Depreciation and amortization Operating key items (see Table 5) 5 13 Adjusted EBITDA 51 46 Adjusted EBITDA - Specialty Additives Operating income \$ 25 \$ 5 Add: Depreciation and amortization 22 21 Operating key items (see Table 5) 18 Adjusted EBITDA 47 \$ 44 Adjusted EBITDA - Intermediates and Solvents Operating income (loss) \$ 18 \$ (3)Add: Depreciation and amortization 3 3 Operating key items (see Table 5) 6 Adjusted EBITDA \$ 21 \$ 6

SEGMENT COMPONENTS OF KEY ITEMS FOR APPLICABLE INCOME **STATEMENT CAPTIONS**

(In millions - preliminary and unaudited)

				Thr	ee Mont	hs Ended	Septem	ber 30, 2	021			
	1.7.		C	sonal are nd		cialty				ocated &	_	
OPERATING INCOME (LOSS)	Life S	ciences	Hous	ehold	Add	litives	and So	olvents		Other		otal
Operating key items:												
Inventory adjustment	\$	- (1)	\$	(2)	\$	-	\$	-	\$	(9)	\$	(2) (10)
Environmental reserve adjustments Asset impairments		(1)		(3)		-		-		(9)		(3)
All other operating income (loss)		31		29		25		18		(18)		85
Operating income (loss)		30		24		25		18		(27)		70
NET INTEREST AND OTHER EXPENSE (INCOME)												
Key items										22		22
All other net interest and other expense (income)										16		16
										38		38
OTHER NET PERIODIC BENEFIT INCOME (COSTS)										(4)		(4)
Key items										(1)		(1)
INCOME TAX EXPENSE (BENEFIT)										(0)		(0)
Tax effect of key items (a) Tax specific key items (b)										(9) (8)		(9) (8)
All other income tax expense (benefit)										15		15
,		<u></u>								(2)		(2)
INCOME (LOSS) FROM CONTINUING OPERATIONS	\$	30	\$	24	\$	25	\$	18	\$	(64)	\$	33
					ee Mont	hs Ended	Septem	ber 30, 2	020			
				sonal are								
				nd	Spe	cialty	Interm	ediates	Unall	ocated &		
	l ifo C	ciences	Hous	ehold	Add	litives	and So	olvents		Other	T	otal
	Lile S	ciences										
OPERATING INCOME (LOSS)	Lile S	ciences										
Operating key items:	<u>Lile S</u> \$		\$	(13)	\$	(18)	\$	(6)	\$	_	\$	(47)
` '		(10)	\$	(13)	\$	(18)	\$	(6)	\$		\$	(47) (8)
Operating key items: Inventory adjustment Environmental reserve adjustments Restructuring, separation and other costs		(10) - -	\$	` - -	\$	-	\$	- -	\$	(8) (22)	\$	(8) (22)
Operating key items: Inventory adjustment Environmental reserve adjustments Restructuring, separation and other costs All other operating income (loss)		(10) - - - 36	\$	- - 26	\$	23	\$	- - 3	\$	(8) (22) (17)	\$	(8) (22) 71
Operating key items: Inventory adjustment Environmental reserve adjustments Restructuring, separation and other costs		(10) - -	\$	` - -	\$	-	\$	- -	\$	(8) (22)	\$	(8) (22)
Operating key items: Inventory adjustment Environmental reserve adjustments Restructuring, separation and other costs All other operating income (loss) Operating income (loss) NET INTEREST AND OTHER EXPENSE (INCOME)		(10) - - - 36	\$	- - 26	\$	23	\$	- - 3	\$	(8) (22) (17) (47)	\$	(8) (22) 71 (6)
Operating key items: Inventory adjustment Environmental reserve adjustments Restructuring, separation and other costs All other operating income (loss) Operating income (loss) NET INTEREST AND OTHER EXPENSE (INCOME) Key items		(10) - - - 36	\$	- - 26	\$	23	\$	- - 3	\$	(8) (22) (17) (47)	\$	(8) (22) 71 (6)
Operating key items: Inventory adjustment Environmental reserve adjustments Restructuring, separation and other costs All other operating income (loss) Operating income (loss) NET INTEREST AND OTHER EXPENSE (INCOME)		(10) - - - 36	\$	- - 26	\$	23	\$	- - 3	\$	(8) (22) (17) (47)	\$	(8) (22) 71 (6)
Operating key items: Inventory adjustment Environmental reserve adjustments Restructuring, separation and other costs All other operating income (loss) Operating income (loss) NET INTEREST AND OTHER EXPENSE (INCOME) Key items		(10) - - - 36	\$	- - 26	\$	23	\$	- - 3	\$	(8) (22) (17) (47)	\$	(8) (22) 71 (6) (11) 17
Operating key items: Inventory adjustment Environmental reserve adjustments Restructuring, separation and other costs All other operating income (loss) Operating income (loss) NET INTEREST AND OTHER EXPENSE (INCOME) Key items All other net interest and other expense OTHER NET PERIODIC BENEFIT INCOME (COSTS) Key items		(10) - - - 36	\$	- - 26	\$	23	\$	- - 3	\$	(8) (22) (17) (47) (11) 17 6	\$ 	(8) (22) 71 (6) (11) 17 6
Operating key items: Inventory adjustment Environmental reserve adjustments Restructuring, separation and other costs All other operating income (loss) Operating income (loss) NET INTEREST AND OTHER EXPENSE (INCOME) Key items All other net interest and other expense OTHER NET PERIODIC BENEFIT INCOME (COSTS)		(10) - - - 36	\$	- - 26	\$	23	\$	- - 3	\$	(8) (22) (17) (47) (11) 17 6		(8) (22) 71 (6) (11) 17 6
Operating key items: Inventory adjustment Environmental reserve adjustments Restructuring, separation and other costs All other operating income (loss) Operating income (loss) NET INTEREST AND OTHER EXPENSE (INCOME) Key items All other net interest and other expense OTHER NET PERIODIC BENEFIT INCOME (COSTS) Key items INCOME TAX EXPENSE (BENEFIT) Tax effect of key items (a) Tax specific key items (b)		(10) - - - 36	\$	- - 26	\$	23	\$	- - 3	\$	(8) (22) (17) (47) (11) 17 6	\$	(8) (22) 71 (6) (11) 17 6
Operating key items: Inventory adjustment Environmental reserve adjustments Restructuring, separation and other costs All other operating income (loss) Operating income (loss) NET INTEREST AND OTHER EXPENSE (INCOME) Key items All other net interest and other expense OTHER NET PERIODIC BENEFIT INCOME (COSTS) Key items INCOME TAX EXPENSE (BENEFIT) Tax effect of key items (a)		(10) - - - 36	\$	- - 26	\$	23	\$	- - 3	\$	(8) (22) (17) (47) (11) 17 6	\$	(8) (22) 71 (6) (11) 17 6
Operating key items: Inventory adjustment Environmental reserve adjustments Restructuring, separation and other costs All other operating income (loss) Operating income (loss) NET INTEREST AND OTHER EXPENSE (INCOME) Key items All other net interest and other expense OTHER NET PERIODIC BENEFIT INCOME (COSTS) Key items INCOME TAX EXPENSE (BENEFIT) Tax effect of key items (a) Tax specific key items (b)		(10) - - - 36	\$	- - 26	\$	23	\$	- - 3	\$	(8) (22) (17) (47) (11) 17 6	\$	(8) (22) 71 (6) (11) 17 6

Represents the tax effect of the key items that are previously identified above.

Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. See Table 7 for additional information.

RECONCILIATION OF CERTAIN NON-GAAP DATA

(In millions - preliminary and unaudited)

Free cash flows (a) Total cash flows provided by operating activities from continuing operations	Three months ended September 30					Year ended September 30				
	2021		2	020		2021	2	2020		
	\$	151	\$	132	\$	466	\$	227		
Adjustments:										
Additions to property, plant and equipment		(31)		(43)		(105)		(133)		
Free cash flows (a) (b) (c)	\$	120	\$	89	\$	361	\$	94		

Free cash flow is defined as cash flows provided (used) by operating activities less additions to property, plant and equipment and other items Ashland has deemed (a)

⁽c) Sales Program.

	Th		Year ended					
		September 30						
Adjusted operating income	2021			2020		021		2020
Operating income (loss) (as reported)	\$	\$ 70		(6)	\$	181	\$	(463)
Key items, before tax:								
Inventory adjustments		2		47		4		51
Restructuring, separation and other costs		-		22		10		58
Environmental reserve adjustments		10		8		43		34
Goodwill impairment		-		-		-		530
Impairments		3	<u></u>			13		-
Adjusted operating income (non-GAAP)	\$	85	\$	71	\$	251	\$	210

ree casn flow is defined as casn flows provided (used) by operating activities less additions to property, plant and equipment and other items Ashland has deemed non-operational (if applicable).

Includes \$9 million and \$7 million of restructuring payments for the three months ended September 30, 2021 and 2020, respectively, and \$44 million and \$30 million of restructuring payments for the twelve months ended September 30, 2021 and 2020, respectively.

Includes \$16 million of cash inflows for the three and \$92 million for the twelve months ended September 30, 2021 associated with the U.S. Accounts Receivable (b)

Ashland Global Holdings Inc. and Consolidated Subsidiaries RECONCILIATION OF CERTAIN NON-GAAP DATA

Table 7

(In millions except per share data - preliminary and unaudited)

	Three months ended September 30					Year ende September				
	2021		2020		2021		2	020		
Income (loss) from continuing operations (as reported)	\$	33	\$	(14)	\$	173	\$	(555)		
Key items, before tax:										
Restructuring, separation and other costs		-		22		10		58		
Unrealized loss (gain) on securities		5		(11)		(21)		(20)		
Goodwill impairment		-		-		-		530		
Inventory adjustments		2		47		4		51		
Environmental reserve adjustments		10		8		43		34		
Accelerated amortization of debt issuance costs		1		-		1		8		
Loss on early retirement of debt		16		-		16		59		
(Gain) loss on pension and other postretirement plan remeasurements		1		(1)		1		(1)		
Net loss (gain) on acquisitions and divestitures		-		-		(11)		-		
Impairments		3		-		13		-		
Key items, before tax		38		65		56		719		
Tax effect of key items (a)		(9)		(13)		(11)		(35)		
Key items, after tax		29		52		45		684		
Tax specific key items:										
Restructuring and separation activity		-		-		(13)		-		
Uncertain tax positions		(14)		3		(53)		3		
Other tax reform related activity		6		5		6		(20)		
Tax specific key items (b)	·	(8)		8		(60)		(17)		
Total key items		21		60		(15)		667		
Adjusted income from continuing operations (non-GAAP)	\$	54	\$	46	\$	158	\$	112		
Amortization expense adjustment (net of tax) (c)		19	-	17		72		67		
Adjusted income from continuing operations (non-GAAP) excluding intangibles	-	<u>·~</u>					-			
amortization expense	\$	73	\$	63	\$	230	\$	179		

Represents the tax effect of the key items that are previously identified above.

Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. These tax specific key items included the following:

Restructuring and separation activity: Includes the impact from company-wide restructuring activities. These adjustments related to various tax impacts including state tax costs, foreign tax costs and other tax account adjustments.
 Uncertain tax positions: Includes the impact from settlement of uncertain tax positions with various tax authorities.
 Other tax reform: Includes the impact of other items related to the Tax Act and other tax law changes enacted during 2020.
 Amortization expense adjustment (net of tax) tax rates were 20% for the three and twelve months ended September 30, 2021 and 24% and 21% for the three and twelve months ended September 30, 2020.

Ashland Global Holdings Inc. and Consolidated Subsidiaries **RECONCILIATION OF CERTAIN NON-GAAP DATA**

(In millions except per share data - preliminary and unaudited)

	Three months ended September 30					Year ende September 2021				
	2021		2020					2020		
Diluted EPS from continuing operations (as reported)	\$	0.55	\$	(0.22)	\$	2.82	\$	(9.16)		
Key items, before tax:										
Restructuring, separation and other costs		-		0.36		0.16		0.95		
Unrealized loss (gain) on securities		0.08		(0.18)		(0.34)		(0.33)		
Goodwill impairment		-		-		-		8.75		
Inventory adjustments		0.03		0.77		0.07		0.83		
Environmental reserve adjustments		0.16		0.13		0.70		0.58		
Accelerated amortization of debt issuance costs		0.02		-		0.02		0.13		
Loss on early retirement of debt		0.26		-		0.26		0.97		
(Gain) loss on pension and other postretirement plan remeasurements		0.02		(0.02)		0.02		(0.01)		
Net loss (gain) on acquisitions and divestitures		-		` -		(0.18)		` -		
Impairments		0.05		-		0.21		-		
Key items, before tax		0.62		1.06		0.92		11.87		
Tax effect of key items (a)		(0.14)		(0.22)		(0.18)		(0.58)		
Key items, after tax		0.48		0.84		0.74		11.29		
Tax specific key items:										
Restructuring and separation activity		-		-		(0.21)		-		
Uncertain tax positions		(0.23)		0.05		(0.87)		0.05		
Other tax reform related activity		0.10		0.08		0.10		(0.33)		
Tax specific key items (b)		(0.13)	•	0.13	•	(0.98)		(0.28)		
Total key items		0.35		0.97		(0.24)	-	11.01		
Adjusted diluted EPS from continuing operations (non-GAAP)	\$	0.90	\$	0.75	\$	2.58	\$	1.85		
Amortization expense adjustment (net of tax) (c)	<u>*</u>	0.32	<u>*</u>	0.28	<u>-</u>	1.17	<u>-</u>	1.08		
		0.32		0.20		1.17	-	1.00		
Adjusted diluted EPS from continuing operations (non-GAAP) excluding intangibles amortization expense	\$	1.22	\$	1.03	\$	3.75	\$	2.93		

⁽a) Represents the tax effect of the key items that are previously identified above.

⁽b) Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. These tax specific key items included the following:

⁻ Restructuring and separation activity: Includes the impact from company-wide restructuring activities. These adjustments related to various tax impacts including state tax costs, foreign tax costs and other tax account adjustments.

⁻ Uncertain tax positions: includes the impact from settlement of uncertain tax positions with various tax authorities.

⁻ Other tax reform: Includes the impact of other items related to the Tax Act and other tax law changes enacted during 2020.

⁽c) Amortization expense adjustment (net of tax) tax rates were 20% for the three and twelve months ended September 30, 2021 and 24% and 21% for the three and twelve months ended September 30, 2020.

Ashland Global Holdings Inc. and Consolidated Subsidiaries **RECONCILIATION OF NON-GAAP DATA – ADJUSTED EBITDA** (In millions except per share data - preliminary and unaudited)

Table 8

		Year ended September 30						
Adjusted EBITDA - Ashland Global Holdings Inc.		021	2020					
Net income (loss)	\$	220	\$	(508)				
Income tax expense (benefit)		(38)		(22)				
Net interest and other expense		56		119				
Depreciation and amortization		244		235				
EBITDA		482		(176)				
Income from discontinued operations (net of taxes)		(47)		(47)				
Key items included in EBITDA:								
Goodwill impairment		-		530				
Restructuring, separation and other costs		10		58				
Environmental reserve adjustments		43		34				
Inventory adjustments		4		51				
Asset impairments		13		-				
Net loss (gain) on acquisitions and divestitures (a)		(11)		-				
Loss (gain) on pension and other postretirement plan remeasurements		1		(1)				
Adjusted EBITDA (b)	\$	495	\$	449				

Excludes income of zero and \$2 million during 2021 and 2020, respectively, related to ongoing adjustment of previous divestiture transactions.

Includes \$6 million and \$4 million during 2021 and 2020, respectively, of new periodic pension and other postretirement costs (income) recognized ratably through the fiscal year. These costs (income) are comprised of service cost, interest cost, expected return on plan assets, and amortization of prior service credit.